Stockscreener 앱 받기
0.721
0.55%
-0.004
Skye Bioscience Inc 주식(SKYE)의 최신 뉴스
Geopolitics Watch: Does Skye Bioscience Inc meet Warren Buffetts criteriaQuarterly Trade Review & Reliable Price Breakout Alerts - baoquankhu1.vn
2026-02-12 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Skye Bioscience, Inc. (SKYE) And Encourages Shareholders to Connect | NDAQ:SKYE | Press Release - Stockhouse
Aug EndMonth: How does IHS Holding Limited compare to its peersJuly 2025 Institutional & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Whats the outlook for Skye Bioscience Incs sectorTrade Analysis Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Retail Trends: Does Skye Bioscience Inc have a competitive edgeJuly 2025 PreEarnings & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
Aug Analyst Calls: Will Skye Bioscience Inc benefit from government policy2025 Valuation Update & Precise Trade Entry Recommendations - baoquankhu1.vn
Movement Recap: Can Skye Bioscience Inc weather a recessionMarket Rally & Long-Term Capital Growth Strategies - baoquankhu1.vn
Here's Why Skye Bioscience (NASDAQ:SKYE) Must Use Its Cash Wisely - Sahm
H.C. Wainwright reiterates Buy rating on Skye Bioscience stock at $20 By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Skye Bioscience stock at $20 - Investing.com Australia
William Blair Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating - 富途牛牛
Skye Bioscience: Nimacimab’s Emerging Clinical Profile and Undervalued Asymmetric Risk/Reward Support Buy Rating - TipRanks
Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year - Benzinga
Skye Bioscience (SKYE) Reports Promising Results from CBeyond Ex - GuruFocus
Skye Bioscience announces 52-week data from Phase 2a CBeyond study of nimacimab - TipRanks
Skye reports positive Cbeyond phase 2a extension interim study results for nimacimab - marketscreener.com
Skye Bioscience Reports Interim Results from Phase 2a Study of Nimacimab - TradingView
Skye, Inc. Announces Interim Results from the Combination Cohort of the Company's Phase 2A Extension Study of Nimacimab - marketscreener.com
Obesity drug combo keeps weight off: Skye study shows 22.3% loss - Stock Titan
Chart Watch: Can Skye Bioscience Inc weather a recessionWeekly Trend Summary & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Skye Reports Positive CBeyond Phase 2a Extension Interim - GlobeNewswire
Skye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment period - MSN
2026-02-01 | Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Stockholders to Inquire about Securities Investigation | NDAQ:SKYE | Press Release - Stockhouse
Skye Bioscience reports positive results for obesity drug nimacimab By Investing.com - Investing.com South Africa
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Skye Bioscience reports positive results for obesity drug nimacimab - Investing.com
Skye Bioscience (SKYE) Highlights Promising Obesity Treatment Re - GuruFocus
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference - The Manila Times
Skye Bioscience Highlights Attributes of its - GlobeNewswire
Investment Report: Can Skye Bioscience Inc beat the S P 500Earnings Miss & Safe Capital Growth Stock Tips - baoquankhu1.vn
Portfolio Shifts: Will CREG stock hit new highs in YEARJuly 2025 WrapUp & Smart Money Movement Tracker - baoquankhu1.vn
2026-01-27 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Stockholders to Learn More About the Investigation | NDAQ:SKYE | Press Release - Stockhouse
Revenue Check: Can Skye Bioscience Inc beat the S P 5002025 Volume Leaders & Weekly Top Stock Performers List - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Investors to Inquire about Securities Investigation - accessnewswire.com
2026-01-25 | Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Investors to Inquire about Securities Investigation | NDAQ:SKYE | Press Release - Stockhouse
Aug Retail: Can Skye Bioscience Inc weather a recessionEarnings Recap Summary & Detailed Earnings Play Strategies - baoquankhu1.vn
Skye Bioscience to Present Research on Nimacimab at Keystone Conference on Obesity Therapeutics - Quiver Quantitative
Skye Bioscience to Present Poster at Keystone Obesity Conference - The Manila Times
Resistance Check: Will Skye Bioscience Inc outperform the market in YEAR2025 Investor Takeaways & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Skye Bioscience, Inc. (SKYE) And Encourages Stockholders to Reach Out - ACCESS Newswire
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Skye Bioscience Faces Class Action for Securities Fraud, Investors Encouraged to Join - Intellectia AI
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Se - GuruFocus
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
SKYE DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Skye Bioscience, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bios - GuruFocus
Skye Bioscience, Inc. Class Action Reminder: Lead Plaintiff Deadline January 16, 2026 - Intellectia AI
SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit - Prime Publishers, Inc.
Skye Bioscience, Inc. (NASDAQ: SKYE) Investor NOTICE: Deadline in Lawsuit on January 16, 2026 - openPR.com
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - TMX Newsfile
Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire
SKYE DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Skye - GlobeNewswire
SKYE DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYE - GlobeNewswire Inc.
1.24%
0.19%
자본화:
|
볼륨(24시간):